Sustao Medical Secures Hundreds of Millions in Series A Funding to Accelerate R&D and Ecosystem Expansion

VCBeat (WeChat: vcbeat) has learned at the earliest opportunity that, recently,Shuzhidao Medical Announces Completion of Hundreds of Millions in Series A Financing. This round of financing was led byLYZZ Capital and JF Capital co-led the investment, with Huatong Capital and IDG CapitalCo-investment. Following this round of financing, Shuzhidao will further enhance the development of its fully automated surgical robot platform and gradually advance clinical trials for related products.

Shu Zhi Dao was founded in 2021 and is aA Platform Company Focused on the Field of Surgical Robotics, committed to building an intelligent consumables ecosystem tailored to the characteristics of robotics technology.

Reviewing the evolution of the industry, surgical procedures have gradually shifted from open to minimally invasive approaches. With the advancement of intelligence, the field of surgical robotics is on the verge of ushering in a new wave of transformation. Currently, medical robots available on the market are limited to basic functions such as navigation, motion constraint, and assistance in performing precise operations. From a technical perspective, surgical robots in the medical field still have considerable room for improvement in terms of full automation and intelligence compared to their industrial counterparts. From a clinical outcome perspective, these surgical robots cannot truly reduce physicians’ workload or enhance surgical efficiency. In response to the aforementioned pain points,Shu Zhi Dao focuses on three major fields: medical aesthetics, oncology, and vascular intervention, deeply deploying more than ten products in the form of “robotic platforms + intelligent consumables,”Fundamentally transform surgical techniques to gradually achieve “fully automated” surgical procedures.

“After centuries of development, existing surgical tools and consumables have gradually reached the optimal solution for manual operation, making it difficult to achieve further breakthroughs based on current design concepts,”Yang Situ, CEO of Shu Zhi Dao, stated“Robotic platforms possess unique operational capabilities; restricting them to controlling only surgical tools and consumables designed for manual operation makes it difficult to fully leverage the advantages of robotic platforms. In the future, a medical robotics company will inevitably emerge to redefine surgical tools and consumables, and we hope that Shu Zhi Dao can become such a company.”

To achieve this goal, Shu Zhi Dao has established foundational technology platforms, including a hybrid robotic arm system, visible light navigation system, adjustable catheter system, and energy system. Meanwhile, it has forged close collaborations with renowned domestic research institutes and leading medical device companies. In the future, the company will further integrate outstanding R&D teams within the industry, continuously expand its technological platforms, and extend its “fully automated solutions” to a broader range of surgical procedures.

Zhang Yong, Managing Partner of LYZZ CapitalIt stated: “The founding team of Shu Zhi Dao integrates source innovation from multiple foundational disciplines with supply chain management capabilities, combining digitalization and artificial intelligence management concepts. It is committed to leveraging an integrated advanced technology platform to address unmet clinical needs. This aligns perfectly with the investment philosophy of LYZZ Capital. We look forward to the early launch of its advanced products that focus on practicality and accessibility, providing more tools for medical experts to benefit a broad patient population.”

Hu Xuyu, Managing Partner of Jifeng Capital“Surgical robots represent the most significant technological innovation in the field of minimally invasive surgery, offering immense potential for future development. Shu Zhi Dao has mastered the underlying technologies of surgical robots, boasts industry-leading R&D and innovation capabilities, and has strategically deployed robotic platforms along with an ecosystem of intelligent consumables across multiple application areas. The company’s founding team demonstrates clear strategic thinking, combining creativity with strong execution. Jifeng Capital is pleased to become a shareholder of Shu Zhi Dao, supporting the company in expanding its fully automated surgical solutions, addressing unmet clinical needs, and delivering benefits to patients.”

Huatong CapitalIt stated: “As high-end intelligent diagnostic and therapeutic equipment, surgical robots can accommodate diverse surgical procedures and varied clinical needs for automated surgery, with related technologies and products experiencing rapid global development. Demand in the Chinese market is robust, and penetration rates are continuously rising. In particular, Shu Zhi Dao’s product pipelines address the vast market potential in medical aesthetics, oncology, and minimally invasive vascular interventional surgeries. Huatong Capital highly recognizes the Shu Zhi Dao team. Many of its developed products are the first and exclusive of their kind in China. Its proprietary, globally leading technologies empower Shu Zhi Dao to achieve success and realize the goal of ‘independent intelligent manufacturing in China,’ thereby benefiting more healthcare professionals and patients.”

IDG Capital“Robotic applications in the medical field are undergoing rapid development. By leveraging its medical robotics platform to simultaneously develop smart consumables, Shu Zhi Dao is poised to redefine the medical robotics market and pioneer a new path toward fully automated surgical solutions. We have full confidence in and high expectations for the Shu Zhi Dao team. The founder possesses keen insights into the healthcare sector, and the R&D team brings extensive experience in related fields. IDG Capital is delighted to partner with such a promising team to build a new ecosystem for medical robotics.”

LYZZ Capital, established in 2014, is a private equity investment firm focused on the healthcare industry. It currently manages three investment funds denominated in US dollars and RMB, with total assets under management nearing RMB 4 billion. LYZZ Capital invests globally in ventures founded by outstanding entrepreneurs, high-quality assets, and advanced technologies, with a particular emphasis on addressing unmet medical needs and tapping into the significant market potential in China. Its portfolio includes industry-leading and innovative companies such as Chipscreen Biosciences, Chentide Pharmaceutical, Neurelis, Wugen, MicroTech Medical, TianGuangShi Biologics, Hanyu Medical, Qingyun Technology, Newman Medical, Qpex Biopharma, and Jumpcode. Leveraging its expertise and global network, LYZZ Capital adds value to its portfolio companies by helping them develop innovative solutions for unmet medical needs and become innovators setting international standards.

Jifeng Capital, established in 2015, is a premier venture capital firm dedicated to the healthcare and medical sectors. By empowering enterprises with comprehensive value-added services and a global perspective, we drive innovation and aim to deliver long-term value to the development of the medical industry and human health. Remaining true to our entrepreneurial roots, we consistently uphold the principles of “professionalism, humility, and diligence.” We are committed to serving entrepreneurs as strategic partners over the long term, helping them build great companies that are rooted in China while embracing a global vision.

Huatong Capital, established in 2020, is an investment firm specializing in the medical device and biopharmaceutical sectors. It focuses on early-stage companies with foundational technologies and high growth potential, as well as select growth-stage companies aligned with its strategic layout. Huatong Capital boasts a multidisciplinary team comprising experts in medical device R&D, clinical practitioners, and life sciences researchers, with professionalism and focused expertise as its defining characteristics. Since its inception, the firm has invested in (or incubated) numerous outstanding companies, achieving steady and rapid growth. We are committed to becoming one of China’s most successful young venture capital funds.

IDG Capital is a globally leading private equity investment firm. With nearly 30 years of development, the company has accumulated over RMB 150 billion in assets under management. IDG Capital focuses on leading enterprises in sectors such as Technology, Media and Telecom (TMT), new consumption and services, culture and entertainment, healthcare, advanced manufacturing, and clean energy. Its investment scope covers all stages, including start-up, growth, mature phases, as well as mergers and acquisitions, with investment sizes ranging from millions to hundreds of millions of US dollars.